WO2011137876A3 - Tolerogenos adyuvados como vacuna de malaria - Google Patents

Tolerogenos adyuvados como vacuna de malaria Download PDF

Info

Publication number
WO2011137876A3
WO2011137876A3 PCT/CU2011/000002 CU2011000002W WO2011137876A3 WO 2011137876 A3 WO2011137876 A3 WO 2011137876A3 CU 2011000002 W CU2011000002 W CU 2011000002W WO 2011137876 A3 WO2011137876 A3 WO 2011137876A3
Authority
WO
WIPO (PCT)
Prior art keywords
tolerogens
malaria
adjuvanted
transmitted infections
vertically transmitted
Prior art date
Application number
PCT/CU2011/000002
Other languages
English (en)
French (fr)
Other versions
WO2011137876A2 (es
Inventor
Oliver Germán Pérez Martín
Maribel PÉREZ CUELLO
Osmir Cabrera Blanco
Julio Antonio BALBOA GONZÁLEZ
Miriam de San Juan Bosco LASTRE GONZÁLEZ
Caridad Caridad Zayas Vignier
Elizabeth GONZÁLEZ AZNAR
Belkis Romeu Alvarez
Original Assignee
Instituto Finlay. Centro De Investigación - Producción De Sueros Y Vacunas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Finlay. Centro De Investigación - Producción De Sueros Y Vacunas filed Critical Instituto Finlay. Centro De Investigación - Producción De Sueros Y Vacunas
Priority to EP11777295.4A priority Critical patent/EP2548572A4/en
Priority to RU2012151576/10A priority patent/RU2012151576A/ru
Publication of WO2011137876A2 publication Critical patent/WO2011137876A2/es
Publication of WO2011137876A3 publication Critical patent/WO2011137876A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con el campo de las composiciones vacunales para el tratamiento efectivo o preventivo de infecciones de transmisión vertical, particularmente la malaria y preferiblemente la humana causada por Plasmodium falciparum. El objetivo técnico que se persigue es usar los tolerógenos trasferidos tempranamente de la madre al feto/recién nacido y formularlos con potentes adyuvantes inductores de respuestas Th1 y T citotóxica para su uso en vacunas profilácticas o terápeuticas contra las infecciones de transmisión vertical y particularmente la malaria. El empleo de estas formulaciones por vía parenteral o mucosal o ambas a la vez en edades tempranas revierte la tolerancia inducida por la transferencia de tolerógenos y con ello inducir respuestas protectivas.
PCT/CU2011/000002 2010-05-05 2011-05-05 Tolerogenos adyuvados como vacuna de malaria WO2011137876A2 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP11777295.4A EP2548572A4 (en) 2010-05-05 2011-05-05 TOLEROGENES ADJUVATED AS VACCINES AGAINST MALARIA
RU2012151576/10A RU2012151576A (ru) 2010-05-05 2011-05-05 Адъювантированные толерогены в качестве вакцины от малярии

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2010-0083 2010-05-05
CU20100083A CU20100083A7 (es) 2010-05-05 2010-05-05 Tolerogenos adyuvados como vacuna de malaria

Publications (2)

Publication Number Publication Date
WO2011137876A2 WO2011137876A2 (es) 2011-11-10
WO2011137876A3 true WO2011137876A3 (es) 2012-01-05

Family

ID=44904160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2011/000002 WO2011137876A2 (es) 2010-05-05 2011-05-05 Tolerogenos adyuvados como vacuna de malaria

Country Status (5)

Country Link
EP (1) EP2548572A4 (es)
AR (1) AR081008A1 (es)
CU (1) CU20100083A7 (es)
RU (1) RU2012151576A (es)
WO (1) WO2011137876A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111433607A (zh) 2017-06-23 2020-07-17 巴塞罗那全球健康研究所 用于妊娠的系统、方法、设备和诊断测试
CN112956668A (zh) * 2021-03-11 2021-06-15 浙江省农业科学院 一种超声辅助生物酶法制备破壁蜂花粉的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060550A2 (en) * 2005-11-23 2007-05-31 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
CU22983A1 (es) 2002-05-08 2004-09-09 Inst Finlay Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas
CU23313A1 (es) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
WO2005030249A1 (en) * 2003-09-30 2005-04-07 Telethon Institute For Child Health Research Immunotherapy method
CU23420A1 (es) 2003-12-30 2009-09-08 Univ De Cambridge Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantes
CU20080215A7 (es) 2008-11-19 2012-06-21 Inst Finlay Vacunas unitemporales

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060550A2 (en) * 2005-11-23 2007-05-31 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRACHO G. ET AL.: "AFCo I, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5.", MALARIA JOURNAL, vol. 8, no. 35, 2009, XP021049967 *
GONZALEZ E. ET AL.: "Mucosal and systemic immune response against Neisseria meningitidis B induced by single time vaccination strategy.", VACCIMONITOR, vol. 18, no. 2, 2009, pages 73 - 75, XP008149172 *
PEREZ O. ET AL.: "New vaccines require potent adjuvants like AFPLl and AFCol.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 66, 2007, pages 271 - 277, XP008149175 *
PEREZ O. ET AL.: "Novel adjuvant base on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen- associated molecular pattern.", IMMUNOLOGY AND CELL BIOLOGY, vol. 84, 2004, pages 603 - 610, XP008108782 *
See also references of EP2548572A4 *

Also Published As

Publication number Publication date
WO2011137876A2 (es) 2011-11-10
AR081008A1 (es) 2012-05-30
EP2548572A4 (en) 2013-12-11
EP2548572A2 (en) 2013-01-23
CU20100083A7 (es) 2012-06-21
RU2012151576A (ru) 2014-06-10

Similar Documents

Publication Publication Date Title
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
MX2013004817A (es) Enfermedad inflamatoria.
MD4754B1 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
WO2009072767A3 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
IL178219A0 (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
PE20151588A1 (es) Vacuna contra el virus del dengue
MX347210B (es) Vacunas combinadas para prevención de infecciones por virus porcino.
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
MX2021007502A (es) Formulaciones y métodos de vacuna de norovirus.
WO2011137876A3 (es) Tolerogenos adyuvados como vacuna de malaria
TN2012000217A1 (en) The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease
IN2014DN08927A (es)
GB201112587D0 (en) Vaccine
WO2015048796A3 (en) Mosaic hiv envelope immunogenic polypeptides
GB2515222A (en) Use of flagellin as a vaccine
WO2013173256A3 (en) New and improved influenza vaccines
HK1170183A1 (zh) 腸球菌病原體的新的抗原及其用作疫苗組分用於治療和/或預防的用途
PH12017500928B1 (en) A rabies composition comprising pika adjuvant
IL312539A (en) Immunogenic structures and vaccines for use in medical and prophylactic treatment of diseases caused by SARS-COV-2
TN2010000338A1 (en) Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant
MX361456B (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una enfermedad parasitaria.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2011777295

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012151576

Country of ref document: RU

Kind code of ref document: A